WILMINGTON (DE), USA, February 05, 2025 / Biotech Newswire / -- Dermaliq Therapeutics, Inc. (Dermaliq) today announces that Ralf Paus, M.D., D.Sc., F.R.S.B. has joined the company’s Scientific and Medical Advisory Board.
Dermaliq is a private biopharmaceutical company dedicated to developing innovative treatments for hair follicle-related diseases. The hair follicle is a vital mini organ in human skin, responsible for producing pigmented hair shafts, but it remains challenging to effectively target with topical drugs.
Prof. Ralf Paus is an authority in clinical dermatology and expert in the biology and pathology of the hair follicle. His expertise will play a pivotal role in guiding the development of DLQ01, a precision drug that specifically targets receptors deep inside the hair follicles to effectively address alopecia and other follicle-related conditions.
“We are very pleased to welcome Prof. Ralf Paus to our Scientific and Medical Advisory Board at this exciting time. His unparalleled expertise in alopecia pathophysiology will be instrumental in guiding our clinical strategy as we advance our pipeline”, said Frank Löscher, PhD Dermaliq CEO. “Our hyliQ technology enables us to precisely target affected hair follicles and delivering a wide range of molecules to develop novel and highly effective and safe topical treatments.”
The company’s lead asset DLQ01 targets prostaglandin receptors to activate hair re-growth in Androgenetic Alopecia (AGA). Its novel, non-hormonal mode of action halts AGA progression, promotes transition of the follicle from telogen (resting) to anagen (growth), prolongs duration of anagen phase, and re-transforms miniaturized hair follicles back into large mini organs that generate thick, long scalp hair shafts. DLQ01 is designed to be the best-in-class AGA treatment in men and women.
"I am excited to collaborate with Dermaliq in advancing innovative solutions for alopecia treatment. Namely for the treatment of androgenic alopecia and alopecia areata, we urgently need better and more effective drugs but must overcome the challenge of low follicular bioavailability without damaging the hair follicle or the skin around it. I am intrigued that Dermaliq’s hyliQ® platform holds out the possibility to significantly increase the bioavailability of topically applied drugs in hair follicles and to thus primarily target these." stated Ralf Paus.
About Ralf Paus, MD, DSc, FRSB
Prof Paus is Research Professor of Dermatology at the University of Miami Miller School of Medicine, Miami, FL, USA, and an academic dermatologist with > 35 years of experience in dermatology and skin and hair research (>720 PubMed-listed publications, H-index: 119). After studying Medicine in Wuerzburg, Vienna, and Berlin, he became fascinated by the biology and pathology of the hair follicle during post-doctoral studies at Yale University, New Haven, CT. Following dermatology residency training and a junior faculty position at the Charite University Hospital, Berlin, his last clinical appointment was as Professor and Vice Chair, Dept. of Dermatology, University Hospital Hamburg-Eppendorf (1999-2004). Since then, Prof Paus has focused on translational hair research and skin neuroendocrinology, first as Head of Experimental Dermatology, University of Luebeck, then as Director of Research, Centre for Dermatology Research, University of Manchester, where he is now the Emeritus Professor of Cutaneous Medicine. He served as Editor of Experimental Dermatology (2007-2021) and is a serial entrepreneur, most recently as Founder & CEO of CUTANEON – Skin & Hair Innovations, Hamburg & Berlin, Germany.
About Dermaliq Therapeutics Inc.
Dermaliq Therapeutics Inc. is a clinical-stage dermatology company developing innovative treatments for skin follicle-related diseases. With a strong pipeline of drug candidates, we are dedicated to advancing medical dermatology through cutting-edge research and technology.
Our mission is to pioneer novel topical therapies that precisely deliver active compounds into follicular and glandular tissues. Using our proprietary hyliQ® technology, we significantly enhance drug bioavailability, enabling the development of highly effective and safe treatments for conditions like alopecia.
About DLQ01
Dermaliq’s lead asset DLQ01 targets the prostaglandin receptor to stimulate hair re-growth. The recent Phase 2a trial demonstrated efficacy, safety, and clear advantages over current standard of care. Favorable FDA-feedback is paving a clear regulatory development path.
Dermaliq is actively seeking strategic partners and investors for its current Series B financing round. This funding will support the continued development of our innovative dermatology pipeline including the phase 2b development of DLQ01 in androgenic alopecia, as we strive to bring breakthrough treatments for Alopecia and other dermatological conditions to market.
Contact
Dermaliq Therapeutics Inc.
Frank Loescher
Chief Executive Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Keywords: Humans; Diffuse alopecia; Alopecia Areata; Hair Follicle; Receptors, Prostaglandin; Biological Availability; Hair; Hair Diseases; Drug Development; North America; Dermaliq Therapeutics; Scientific and Medical Advisory Board; Ralf Paus; Alopecia; Hair follicle; DLQ01; Prostaglandin receptors; Androgenetic Alopecia (AGA); hyliQ technology; Topical treatments; Hair re-growth; Phase 2a trial; Series B financing; Follicular and glandular tissues; Skin neuroendocrinology; Experimental Dermatology
Source: Biotech Newswire